Safety and Efficacy of Oral AGN 203818 for the Relief of Irritable Bowel Syndrome Pain
Primary Purpose
Irritable Bowel Syndrome
Status
Terminated
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
AGN 203818
AGN 203818
AGN 203818
placebo
Sponsored by
About this trial
This is an interventional treatment trial for Irritable Bowel Syndrome
Eligibility Criteria
Inclusion Criteria:
- Diagnosis of Irritable Bowel Syndrome
- Moderate or severe IBS pain
Exclusion Criteria:
- Any other uncontrolled disease
- Pregnant or nursing females
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm Type
Experimental
Experimental
Experimental
Placebo Comparator
Arm Label
AGN 203818 3 mg
AGN 203818 20 mg
AGN 203818 60 mg
Placebo
Arm Description
Part A: AGN 203818 3mg capsule every 12 hours for 4 weeks
Part A: AGN 203818 20mg capsule every 12 hours for 4 weeks
Part A: AGN 203818 60mg capsule every 12 hours for 4 weeks
Part A: Placebo capsule every 12 hours for 4 weeks
Outcomes
Primary Outcome Measures
Change From Baseline in Mean Highest-Average-Pain Score at Week 4
Change from baseline in mean highest-average-pain score at Week 4. The mean highest-average-pain score was the average of the 7 highest daily-average-pain scores obtained over the 14 days prior to the Week 4 visit. Patients recorded their daily-average-pain on an 11-point scale (where 0 equals no pain and 10 equals worst pain imaginable). A negative number change from baseline represents a decrease in average pain (improvement).
Secondary Outcome Measures
Percentage of Patients Who Rated Their Condition as Improved on the Subject Global Impression of Change (SGIC) at Week 4
Percentage of patients who rated their condition as improved on the SGIC at week 4. The SGIC score was assessed using a 7-point scale (score of 1=very much improved; 2=much improved; 3=minimally improved; 4=no change; 5=minimally worse; 6=much worse; 7=very much worse). Patients self-evaluated their overall change in symptoms (relief from symptoms of abdominal discomfort, pain, and altered bowel habits). An "improved" condition was defined as a score of 1, 2, or 3.
Percentage of Patients Who Experienced Adequate Relief of Irritable Bowel Syndrome (IBS) Pain (AR-IBS) at Week 4
Percentage of patients who experienced AR-IBS at week 4. The AR-IBS is a self-evaluation by the patient of their perception of adequate relief of IBS pain over the last 7 days following treatment as compared to IBS pain before receiving treatment. Patients respond with either a "Yes" or "No", where "Yes" indicated adequate relief of pain and "No" indicated no relief from pain.
Change From Baseline in Frequency of Bowel Movements at Week 4 Using the Bristol Stool Scale (BSS)
Change from baseline in the frequency of bowel movements per day using the BSS. The BSS categorizes stool based on the patient's description of its consistency. Patients are classified into 3 IBS subtypes according to their predominant stool patterns (C=constipation; D=diarrhea; M=mixed). A positive change from baseline in the IBS-C indicates improvement and a negative change from baseline in the IBS-D and IBS-M indicates improvement.
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT00441766
Brief Title
Safety and Efficacy of Oral AGN 203818 for the Relief of Irritable Bowel Syndrome Pain
Study Type
Interventional
2. Study Status
Record Verification Date
December 2011
Overall Recruitment Status
Terminated
Why Stopped
Study was terminated due to company decision after Part A. Part B was never conducted
Study Start Date
March 2007 (undefined)
Primary Completion Date
February 2008 (Actual)
Study Completion Date
February 2008 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Allergan
4. Oversight
5. Study Description
Brief Summary
This study will explore the safety and effectiveness of different doses of AGN 203818 in relieving Irritable Bowel Syndrome pain. The study is being conducted in 2 parts. Part A enrolled 213 pts dosed with either 3, 20, 60 mg AGN 203818 or placebo over 4 week treatment duration. Part B will enroll 320 pts and dose with either 60, 100, 160 mg BID AGN 203818 or placebo over 12 week treatment duration.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Irritable Bowel Syndrome
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
213 (Actual)
8. Arms, Groups, and Interventions
Arm Title
AGN 203818 3 mg
Arm Type
Experimental
Arm Description
Part A: AGN 203818 3mg capsule every 12 hours for 4 weeks
Arm Title
AGN 203818 20 mg
Arm Type
Experimental
Arm Description
Part A: AGN 203818 20mg capsule every 12 hours for 4 weeks
Arm Title
AGN 203818 60 mg
Arm Type
Experimental
Arm Description
Part A: AGN 203818 60mg capsule every 12 hours for 4 weeks
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Part A: Placebo capsule every 12 hours for 4 weeks
Intervention Type
Drug
Intervention Name(s)
AGN 203818
Intervention Description
Part A: 3 mg AGN203818 capsule every 12 hours for 4 weeks
Intervention Type
Drug
Intervention Name(s)
AGN 203818
Intervention Description
Part A: 20 mg AGN203818 capsule every 12 hours for 4 weeks
Intervention Type
Drug
Intervention Name(s)
AGN 203818
Intervention Description
Part A: 60 mg AGN203818 capsule every 12 hours for 4 weeks
Intervention Type
Drug
Intervention Name(s)
placebo
Intervention Description
Part A: placebo capsule every 12 hours for 4 weeks
Primary Outcome Measure Information:
Title
Change From Baseline in Mean Highest-Average-Pain Score at Week 4
Description
Change from baseline in mean highest-average-pain score at Week 4. The mean highest-average-pain score was the average of the 7 highest daily-average-pain scores obtained over the 14 days prior to the Week 4 visit. Patients recorded their daily-average-pain on an 11-point scale (where 0 equals no pain and 10 equals worst pain imaginable). A negative number change from baseline represents a decrease in average pain (improvement).
Time Frame
Baseline, Week 4
Secondary Outcome Measure Information:
Title
Percentage of Patients Who Rated Their Condition as Improved on the Subject Global Impression of Change (SGIC) at Week 4
Description
Percentage of patients who rated their condition as improved on the SGIC at week 4. The SGIC score was assessed using a 7-point scale (score of 1=very much improved; 2=much improved; 3=minimally improved; 4=no change; 5=minimally worse; 6=much worse; 7=very much worse). Patients self-evaluated their overall change in symptoms (relief from symptoms of abdominal discomfort, pain, and altered bowel habits). An "improved" condition was defined as a score of 1, 2, or 3.
Time Frame
Week 4
Title
Percentage of Patients Who Experienced Adequate Relief of Irritable Bowel Syndrome (IBS) Pain (AR-IBS) at Week 4
Description
Percentage of patients who experienced AR-IBS at week 4. The AR-IBS is a self-evaluation by the patient of their perception of adequate relief of IBS pain over the last 7 days following treatment as compared to IBS pain before receiving treatment. Patients respond with either a "Yes" or "No", where "Yes" indicated adequate relief of pain and "No" indicated no relief from pain.
Time Frame
Week 4
Title
Change From Baseline in Frequency of Bowel Movements at Week 4 Using the Bristol Stool Scale (BSS)
Description
Change from baseline in the frequency of bowel movements per day using the BSS. The BSS categorizes stool based on the patient's description of its consistency. Patients are classified into 3 IBS subtypes according to their predominant stool patterns (C=constipation; D=diarrhea; M=mixed). A positive change from baseline in the IBS-C indicates improvement and a negative change from baseline in the IBS-D and IBS-M indicates improvement.
Time Frame
Baseline, Week 4
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Diagnosis of Irritable Bowel Syndrome
Moderate or severe IBS pain
Exclusion Criteria:
Any other uncontrolled disease
Pregnant or nursing females
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Medical Director
Organizational Affiliation
Allergan
Official's Role
Study Director
Facility Information:
City
Orange
State/Province
California
Country
United States
12. IPD Sharing Statement
Learn more about this trial
Safety and Efficacy of Oral AGN 203818 for the Relief of Irritable Bowel Syndrome Pain
We'll reach out to this number within 24 hrs